article thumbnail

Heart failure services from the community perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.

article thumbnail

Trends in the Clinical Characteristics and Outcome of Infective Endocarditis: A Nationwide Study From 2016 to 2021

Journal of the American Heart Association

This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2021. A total of 17 407 patients with IE (37.8%

article thumbnail

Digital Consults to Enhance Heart Failure Treatment: The ADMINISTER Trial

Cardiology Update

Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).

article thumbnail

Heart failure services from the hospital perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a significant problem in the UK with variation in services across the country. Here we describe the findings from a cross-sectional survey of HF services in the UK performed between September 2021 and February 2022. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF.

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

article thumbnail

Reversals in the Decline of Heart Failure Mortality in the US, 1999 to 2021

JAMA Cardiology

This cohort study evaluates recent reversals in declines in cardiovascular mortality and whether they vary across sociodemographic categories.

article thumbnail

Mapping the intersection of sudden cardiac death and COVID-19: a comprehensive bibliometric analysis (2020–2024)

Frontiers in Cardiovascular Medicine

The peak in publications occurred in 2021, driven by the urgent need to understand the cardiovascular implications of COVID-19. Keyword analysis identified “COVID-19” and “SARS-CoV-2” as dominant themes, with related terms like myocarditis and heart failure reflecting major cardiovascular concerns. and Guo T et al.